S&P 500   4,269.46 (-0.44%)
DOW   33,318.87 (-0.34%)
QQQ   359.21 (-0.57%)
AAPL   172.79 (-0.55%)
MSFT   320.51 (-0.40%)
META   305.39 (-0.47%)
GOOGL   133.46 (-0.53%)
AMZN   128.46 (-0.77%)
TSLA   247.41 (-1.67%)
NVDA   448.24 (+0.09%)
NIO   8.65 (-1.59%)
BABA   84.56 (-2.28%)
AMD   102.29 (-0.95%)
T   14.65 (-0.14%)
F   12.14 (-1.38%)
MU   67.60 (-0.53%)
CGC   0.71 (-3.05%)
GE   108.66 (-0.12%)
DIS   81.05 (-0.76%)
AMC   8.04 (-1.35%)
PFE   33.90 (-0.12%)
PYPL   57.97 (-1.01%)
NFLX   376.78 (-0.93%)
S&P 500   4,269.46 (-0.44%)
DOW   33,318.87 (-0.34%)
QQQ   359.21 (-0.57%)
AAPL   172.79 (-0.55%)
MSFT   320.51 (-0.40%)
META   305.39 (-0.47%)
GOOGL   133.46 (-0.53%)
AMZN   128.46 (-0.77%)
TSLA   247.41 (-1.67%)
NVDA   448.24 (+0.09%)
NIO   8.65 (-1.59%)
BABA   84.56 (-2.28%)
AMD   102.29 (-0.95%)
T   14.65 (-0.14%)
F   12.14 (-1.38%)
MU   67.60 (-0.53%)
CGC   0.71 (-3.05%)
GE   108.66 (-0.12%)
DIS   81.05 (-0.76%)
AMC   8.04 (-1.35%)
PFE   33.90 (-0.12%)
PYPL   57.97 (-1.01%)
NFLX   376.78 (-0.93%)
S&P 500   4,269.46 (-0.44%)
DOW   33,318.87 (-0.34%)
QQQ   359.21 (-0.57%)
AAPL   172.79 (-0.55%)
MSFT   320.51 (-0.40%)
META   305.39 (-0.47%)
GOOGL   133.46 (-0.53%)
AMZN   128.46 (-0.77%)
TSLA   247.41 (-1.67%)
NVDA   448.24 (+0.09%)
NIO   8.65 (-1.59%)
BABA   84.56 (-2.28%)
AMD   102.29 (-0.95%)
T   14.65 (-0.14%)
F   12.14 (-1.38%)
MU   67.60 (-0.53%)
CGC   0.71 (-3.05%)
GE   108.66 (-0.12%)
DIS   81.05 (-0.76%)
AMC   8.04 (-1.35%)
PFE   33.90 (-0.12%)
PYPL   57.97 (-1.01%)
NFLX   376.78 (-0.93%)
S&P 500   4,269.46 (-0.44%)
DOW   33,318.87 (-0.34%)
QQQ   359.21 (-0.57%)
AAPL   172.79 (-0.55%)
MSFT   320.51 (-0.40%)
META   305.39 (-0.47%)
GOOGL   133.46 (-0.53%)
AMZN   128.46 (-0.77%)
TSLA   247.41 (-1.67%)
NVDA   448.24 (+0.09%)
NIO   8.65 (-1.59%)
BABA   84.56 (-2.28%)
AMD   102.29 (-0.95%)
T   14.65 (-0.14%)
F   12.14 (-1.38%)
MU   67.60 (-0.53%)
CGC   0.71 (-3.05%)
GE   108.66 (-0.12%)
DIS   81.05 (-0.76%)
AMC   8.04 (-1.35%)
PFE   33.90 (-0.12%)
PYPL   57.97 (-1.01%)
NFLX   376.78 (-0.93%)
NASDAQ:ASND

Ascendis Pharma A/S (ASND) Stock Forecast, Price & News

$90.30
-3.34 (-3.57%)
(As of 09:32 AM ET)
Compare
Today's Range
$90.30
▼
$91.90
50-Day Range
$86.67
▼
$103.97
52-Week Range
$64.33
▼
$134.52
Volume
1,121 shs
Average Volume
452,232 shs
Market Capitalization
$5.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$145.20
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Ascendis Pharma A/S MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
59.3% Upside
$145.20 Price Target
Short Interest
Bearish
7.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.16mentions of Ascendis Pharma A/S in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($9.91) to ($8.31) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

587th out of 975 stocks

Pharmaceutical Preparations Industry

271st out of 455 stocks

See Top Rated MarketRank™ Stocks Here

ASND stock logo

About Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

ASND Price History

ASND Stock News Headlines

October 2, 2023 | finance.yahoo.com
Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting
September 30, 2023 | americanbankingnews.com
Ascendis Pharma A/S (NASDAQ:ASND) Stock Crosses Above 50 Day Moving Average of $95.16
October 3, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 23, 2023 | finance.yahoo.com
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency
September 22, 2023 | finance.yahoo.com
Here’s What Caused the Volatility in Ascendis Pharma A/S (ASND)
September 15, 2023 | markets.businessinsider.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND) and Laboratory (LH)
September 15, 2023 | finance.yahoo.com
Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?
September 15, 2023 | finance.yahoo.com
Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 14, 2023 | finance.yahoo.com
Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism
September 12, 2023 | msn.com
Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge
September 10, 2023 | finance.yahoo.com
Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week
September 7, 2023 | markets.businessinsider.com
Berenberg Bank Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
September 7, 2023 | markets.businessinsider.com
Bank of America Securities Sticks to Its Buy Rating for Ascendis Pharma (ASND)
September 6, 2023 | finance.yahoo.com
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript
September 6, 2023 | finance.yahoo.com
Is Ascendis Pharma A/S (ASND) Too Good to Be True? A Comprehensive Analysis of a Potential ...
September 6, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Abbott Labs (ABT) and Thermo Fisher (TMO)
September 5, 2023 | finance.yahoo.com
New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism
September 5, 2023 | finance.yahoo.com
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
September 5, 2023 | finance.yahoo.com
Ascendis Pharma Reports Second Quarter 2023 Financial Results
September 5, 2023 | finance.yahoo.com
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 4, 2023 | markets.businessinsider.com
Here's what Wall Street expects from Ascendis Pharma (spons ADRs)'s earnings report
August 28, 2023 | finance.yahoo.com
Wall Street Analysts Predict a 41.43% Upside in Ascendis Pharma A/S (ASND): Here's What You Should Know
August 28, 2023 | finance.yahoo.com
Wall Street Analysts Predict a 41.43% Upside in Ascendis Pharma A/S (ASND): Here's What You Should Know
August 24, 2023 | finance.yahoo.com
Here’s Why Ascendis Pharma A/S (ASND) Declined in Q2
August 24, 2023 | finance.yahoo.com
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
August 15, 2023 | finance.yahoo.com
Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023
See More Headlines
Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ASND Company Calendar

Last Earnings
9/05/2023
Today
10/03/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ASND
CUSIP
N/A
CIK
1612042
Web
www.ascendispharma.com
Phone
(457) 022-2244
Fax
45-3694-4010
Employees
797
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$145.20
High Stock Price Forecast
$192.00
Low Stock Price Forecast
$113.00
Forecasted Upside/Downside
+59.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($11.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-614,450,000.00
Net Margins
-500.93%
Pretax Margin
-500.07%
Return on Equity
-257.83%
Return on Assets
-58.01%

Debt

Debt-to-Equity Ratio
7.39
Current Ratio
3.52
Quick Ratio
2.65

Sales & Book Value

Annual Sales
$119.17 million
Price / Sales
43.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.87 per share
Price / Book
18.71

Miscellaneous

Outstanding Shares
57,152,000
Free Float
34,291,000
Market Cap
$5.21 billion
Optionable
Optionable
Beta
0.50
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Jan Moller Mikkelsen (Age 63)
    Pres, CEO, Member of Exec. Board & Exec. Director
  • Mr. Scott T. Smith (Age 49)
    CFO, Exec. VP & Member of Exec. Board
  • Ms. Lotte Sonderbjerg (Age 62)
    Exec. VP, Chief Admin. Officer & Member of the Exec. Board
  • Mr. Michael Wolff Jensen L.L.M. (Age 52)
    Exec. VP, Chief Legal Officer & Member of the Exec. Board
  • Mr. Peter Rasmussen (Age 54)
    VP of Fin. & Principal Accounting Officer
  • Mr. Timothy J. Lee
    Sr. Director of Investor Relations
  • Mr. Flemming Steen Jensen (Age 62)
    Exec. VP of Product Supply & Quality - Endocrinology Rare Diseases
  • Dr. Kennett Sprogoe Ph.D. (Age 44)
    Exec. VP of Research & Product Devel.
  • Dr. Birgitte Volck M.D. (Age 61)
    Ph.D., Exec. VP and Head of Clinical Devel. & Medical Affairs - Endocrinology Rare Diseases
  • Dr. Jens Sigurd Okkels Ph.D. (Age 62)
    Exec. VP of Product Devel.

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ASND Stock - Frequently Asked Questions

Should I buy or sell Ascendis Pharma A/S stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ASND shares.
View ASND analyst ratings or view top-rated stocks.

What is Ascendis Pharma A/S's stock price forecast for 2023?

10 Wall Street analysts have issued 12 month price objectives for Ascendis Pharma A/S's stock. Their ASND share price forecasts range from $113.00 to $192.00. On average, they anticipate the company's share price to reach $145.20 in the next twelve months. This suggests a possible upside of 59.3% from the stock's current price.
View analysts price targets for ASND or view top-rated stocks among Wall Street analysts.

How have ASND shares performed in 2023?

Ascendis Pharma A/S's stock was trading at $122.13 at the start of the year. Since then, ASND shares have decreased by 25.4% and is now trading at $91.13.
View the best growth stocks for 2023 here.

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a decrease in short interest in September. As of September 15th, there was short interest totaling 4,060,000 shares, a decrease of 10.6% from the August 31st total of 4,540,000 shares. Based on an average daily trading volume, of 267,600 shares, the days-to-cover ratio is currently 15.2 days.
View Ascendis Pharma A/S's Short Interest.

When is Ascendis Pharma A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ASND earnings forecast.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Tuesday, September, 5th. The biotechnology company reported ($2.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.68) by $0.33. The biotechnology company earned $51.59 million during the quarter, compared to analyst estimates of $41.73 million. Ascendis Pharma A/S had a negative net margin of 500.93% and a negative trailing twelve-month return on equity of 257.83%.

What ETFs hold Ascendis Pharma A/S's stock?

ETFs with the largest weight of Ascendis Pharma A/S (NASDAQ:ASND) stock in their portfolio include Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Virtus LifeSci Biotech Products ETF (BBP), BNY Mellon Innovators ETF (BKIV), Global X Guru Index ETF (GURU), Harbor Disruptive Innovation ETF (INNO), Fidelity Disruptive Medicine ETF (FMED) and American CenturyFocused Dynamic Growth ETF (FDG).

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $91.13.

How much money does Ascendis Pharma A/S make?

Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $5.21 billion and generates $119.17 million in revenue each year. The biotechnology company earns $-614,450,000.00 in net income (profit) each year or ($11.30) on an earnings per share basis.

How many employees does Ascendis Pharma A/S have?

The company employs 797 workers across the globe.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for the company is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010.

This page (NASDAQ:ASND) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -